A UC Berkeley-led team has engineered lipid nanoparticles that switch their electrical charge depending on acidity, a design meant to deliver mRNA and other genetic material without the inflammation conventional nanoparticles can cause, according to a paper published online Sept. 8 in Nature Nanotechnology (opens in new tab) and a Berkeley Engineering (opens in new tab) announcement Thursday.

Lipid nanoparticles are used to deliver mRNA vaccines and therapies. The paper says the nanoparticles’ ionizable lipid and the way they break out of cell compartments called endosomes are the main sources of their toxicity, but are also essential for delivering genetic material.

The researchers added a carboxylic acid to the ionizable lipid, producing what they call S-lipids, which switch their charge between pH 7.4 and pH 4.0, the paper says. “But when they circulate in our near-neutral blood, they flip to a negatively charged state that helps mitigate toxicity and avoids triggering inflammation,” Dengpan Liang, a postdoctoral researcher in Murthy’s lab and the study’s co-first author, said in the announcement. According to the paper, the resulting nanoparticles delivered their cargo without activating several inflammation pathways, including TLR4 and complement.

In a mouse model of acute lung injury, the switchable nanoparticles were better at treating the condition than traditional lipid nanoparticles, the paper reports. Berkeley said that in human blood cells, they were the only class of lipid nanoparticle among six commonly used types tested that did not trigger inflammation.

“Until now, the idea of making lipid nanoparticles that are negatively charged, which delivered mRNA, seemed impossible,” said Niren Murthy, the Berkeley bioengineering professor who led the study. Murthy and Liang envision the nanoparticle first being used for protein replacement therapy in the liver for patients with ornithine transcarbamylase deficiency, a rare inherited disorder that leaves the body unable to clear ammonia from the blood, Berkeley said.

The first generation of the nanoparticles reaches only the liver and spleen, according to Berkeley, and the team has developed about 20 lipids that perform well. The researchers say they plan to make the lipids more degradable and to target other organs.